HK Stock Market Move | HAIXI PHARMA (02637) reached a new high this morning but fell back later in the afternoon, dropping more than 25% at one point. Prior to this, the stock price had doubled in the past month.

HAIXI PHARMA (02637) fell more than 25% in the afternoon, after rising more than 7% this morning, reaching a historical high of 302.4 Hong Kong dollars. As of the time of writing, it has fallen by 21.87% to 219.4 Hong Kong dollars, with a trading volume of 382 million Hong Kong dollars. In terms of news, HAIXI PHARMA officially listed on the Hong Kong Stock Exchange on October 20 last year, and its stock price has fluctuated and climbed since then. Starting from late March this year, the company's stock price has rapidly risen from around 140 Hong Kong dollars per share, doubling in just one month. It is worth noting that on April 20, HAIXI PHARMA's listing reached its six-month anniversary and faced a lifting of restrictions, with cornerstone investors holding 1.9817 million shares, accounting for 2.52% of the total share capital after issuance. Shenwan Hongyuan Group's recent research report pointed out that HAIXI PHARMA has achieved profitability for five consecutive years through its generic drug business, with overall operating revenue and profit steadily increasing. By 2025, operating revenue is expected to reach 582 million yuan, a year-on-year increase of 25%, and net profit to reach 177 million yuan, a year-on-year increase of 30%. After achieving stable and sustained profitability, the company is vigorously promoting innovative drug research and development. The fastest progressing drug, C019199, is about to enter Phase III clinical trials, while HXP056, with the potential to become a globally significant product, is expected to undergo data verification.